Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

A panelist discusses how patient-reported outcomes have transformed their ability to deliver more personalized care ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

About Polycythemia Vera (PV) PV is a rare and potentially life-threatening hematologic disease characterized by the overproduction of red blood cells, which significantly increases the risk of ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.